Pharmacyclics PCYC 1141 (Bruton's Tyrosine Kinase Inhibitor, Treatment for Follicular Lymphoma)

Trial description
A Multicentre, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
Contact name
Dr George Follows
Trial start date
Friday, July 27, 2018
Trial end date
Friday, May 31, 2019
Trial tumour type
Haematological
Show on Radiotherapy
No